Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years: https://g.foolcdn.com/editorial/images/741950/a-couple-reviewing-a-document-at-home.jpg
3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years

Want a good dividend stock to own? Don't focus just on the yield itself. When it comes to long-term dividend income, it's important to consider businesses that are growing and that have the

3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years: https://g.foolcdn.com/editorial/images/741950/a-couple-reviewing-a-document-at-home.jpg
3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years

Want a good dividend stock to own? Don't focus just on the yield itself. When it comes to long-term dividend income, it's important to consider businesses that are growing and that have the

3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years: https://g.foolcdn.com/editorial/images/741950/a-couple-reviewing-a-document-at-home.jpg
3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years

Want a good dividend stock to own? Don't focus just on the yield itself. When it comes to long-term dividend income, it's important to consider businesses that are growing and that have the

1 Green Flag and 1 Red Flag for Tilray Stock: https://g.foolcdn.com/editorial/images/742201/a-person-holding-a-cannabis-plant.jpeg
1 Green Flag and 1 Red Flag for Tilray Stock

Canadian cannabis company Tilray Brands (NASDAQ: TLRY) has been on the right track ever since it merged with rival Aphria in 2021. From an operational standpoint, it had been consistently

3 High-Yielding Dividend Stocks to Buy and Hold for Decades: https://g.foolcdn.com/editorial/images/741947/a-couple-reviewing-a-statement.jpg
3 High-Yielding Dividend Stocks to Buy and Hold for Decades

According to a recent Ipsos poll, one in five Americans don't expect to retire, and that's largely because they don't feel they can afford to do so. One way for Americans to improve their financial

This Is Arguably the Single Best Stock to Buy Right Now: https://g.foolcdn.com/editorial/images/742358/light-bulbs-with-dollar-sign-person-looking-up.jpg
This Is Arguably the Single Best Stock to Buy Right Now

What's the single best stock to buy right now? Ask five different investors and you'll probably get five different answers.

The problem, of course, is that defining what makes a given candidate the

This Is Arguably the Single Best Stock to Buy Right Now: https://g.foolcdn.com/editorial/images/742358/light-bulbs-with-dollar-sign-person-looking-up.jpg
This Is Arguably the Single Best Stock to Buy Right Now

What's the single best stock to buy right now? Ask five different investors and you'll probably get five different answers.

The problem, of course, is that defining what makes a given candidate the

This Is Arguably the Single Best Stock to Buy Right Now: https://g.foolcdn.com/editorial/images/742358/light-bulbs-with-dollar-sign-person-looking-up.jpg
This Is Arguably the Single Best Stock to Buy Right Now

What's the single best stock to buy right now? Ask five different investors and you'll probably get five different answers.

The problem, of course, is that defining what makes a given candidate the

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Sarepta Therapeutics (NASDAQ: SRPT)Q2 2023 Earnings CallAug 02, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q2 2023 Earnings CallAug 02, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Shares of Blueprint Medicines Are Falling Wednesday: https://g.foolcdn.com/editorial/images/742419/nurse-tending-patient-in-intensive-care.jpg
Why Shares of Blueprint Medicines Are Falling Wednesday

Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27%

This Deep Value Stock Is a Strong Buy: https://g.foolcdn.com/editorial/images/742082/a-doctor-examines-a-patient.jpg
This Deep Value Stock Is a Strong Buy

Value investing can be a powerful strategy. Buying businesses for less than they are worth can limit your risk of significant capital losses, and it can increase your chances of future upside.

The

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Exelixis (EXEL) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Exelixis (EXEL) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q2 2023 Earnings CallAug 01, 2023, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (PFE) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Pfizer (PFE) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q2 2023 Earnings CallAug 01, 2023, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (PFE) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Pfizer (PFE) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q2 2023 Earnings CallAug 01, 2023, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Merck (MRK) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Merck (MRK) Q2 2023 Earnings Call Transcript

Image source: The Motley Fool.

Merck (NYSE: MRK)Q2 2023 Earnings CallAug 01, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August: https://g.foolcdn.com/editorial/images/741692/scientists-in-a-lab-smiling.jpg
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August

Any time is a good time for income investors to buy dividend stocks. But certain times are better than others for specific stocks.

I think that's the case for several great picks with a new month

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.: https://g.foolcdn.com/editorial/images/741916/gettyimages-1135625573.jpg
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.

Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.: https://g.foolcdn.com/editorial/images/741916/gettyimages-1135625573.jpg
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.

Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.: https://g.foolcdn.com/editorial/images/741916/gettyimages-1135625573.jpg
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.

Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in